|
DDHD2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.21884749357559E-14 |
| Normal-vs-Stage2 |
8.38270000080854E-08 |
| Normal-vs-Stage3 |
3.29802851695149E-12 |
| Normal-vs-Stage4 |
2.85249601716941E-11 |
| Stage1-vs-Stage2 |
7.344200E-01 |
| Stage1-vs-Stage3 |
3.688800E-01 |
| Stage1-vs-Stage4 |
2.575000E-01 |
| Stage2-vs-Stage3 |
3.707400E-01 |
| Stage2-vs-Stage4 |
2.693200E-01 |
| Stage3-vs-Stage4 |
7.895000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.637070E-04 |
| Normal-vs-Asian |
3.25589999961018E-07 |
| Caucasian-vs-AfricanAmerican |
2.179200E-01 |
| Caucasian-vs-Asian |
2.238800E-01 |
| AfricanAmerican-vs-Asian |
7.842000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.39173134022985E-13 |
| Normal-vs-Female |
1.62792002100787E-12 |
| Male-vs-Female |
7.139800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.22709620242745E-11 |
| Normal-vs-Age(41-60Yrs) |
9.10382880192628E-15 |
| Normal-vs-Age(61-80Yrs) |
3.3530955789729E-11 |
| Normal-vs-Age(81-100Yrs) |
1.969970E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.101600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.225000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.508000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.094600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.479000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.743000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.877370E-01 |
| Classical-VS-Follicular |
3.452200E-01 |
| Classical-VS-Other |
6.014600E-01 |
| Classical-VS-Normal |
1.75748304798162E-12 |
| Tall-VS-Follicular |
5.597200E-01 |
| Tall-VS-Other |
8.749600E-01 |
| Tall-VS-Normal |
3.78290000435655E-08 |
| Follicular-VS-Other |
8.599400E-01 |
| Follicular-VS-Normal |
5.22869969543649E-10 |
| Other-VS-Normal |
2.542800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.03010957938932E-14 |
| Normal-vs-N1 |
7.32219840315906E-11 |
| N0-vs-N1 |
4.191400E-01 |
|
|
